BioLine RX BLRX 深 沪
已收盘 08-01 16:00:00 美东时间
3.87
-0.110
-2.76%
华盛通- 最 高3.9699
- 今 开3.85
- 成交量 1.79万股
- 最 低 3.71
- 昨 收 3.98
- 总市值 1440.03万
- 52周最高 35.024
- 市盈率 静 --
- 换手率 0.48%
- 52周最低 2.3001
- 委 比 67.93%
- 总股本 372.10万
- 历史最高 4122.00
- 量 比 0.53
- 振 幅 6.53%
- 历史最低 3.26
- 每 手 1
- 风险率 9.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Where BioLine Rx Stands With Analysts
In the latest quarter, 4 analysts provided ratings for BioLine Rx (NASDAQ:BLRX)...
06-17 20:00
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Lyra Therapeutics (NASDAQ:LYRA) stock rose 376.8% to $23.5 during Mond...
06-03 01:06
美股大行评级 | 潜在涨幅746.15%！Intrusion获Ascendiant Capital升目标价至11美元，维持"买入"评级
潜在涨幅746.15%！Intrusion获Ascendiant Capital升目标价至11美元，维持"买入"评级
06-02 13:32
Why Is Nano-Cap BioLineRx Stock Surging On Friday?
BioLineRx shares new data from its Phase 2 pancreatic cancer trial, showing strong response rates and durable outcomes with motixafortide combination.
05-31 01:58
Why UiPath Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Shares of UiPath Inc. (NYSE:PATH) rose sharply in today's pre-market trading af...
05-30 19:59
Market-Moving News for May 30th
REGN: -13% | Regeneron shares are trading lower after the company and Sanofi said the AERIFY-1 study met its primary endpoint but the AERIFY-2 study did not. GAP: -18% | Gap shares are trading lower after
05-30 19:15
美股大行评级 | 拼多多遭多家大行下调评级！Redburn Atlantic首予博通"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1134767544930545665.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持AnaptysBio(ANAB)"买入"评级，目标价从54美元升至90美元</p> <p>• Canaccord Genuity：维持Bridger Aerospace Gr(BAER)"买入"评
05-29 09:53
HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $26 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $26 price target.
05-28 18:49
BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update
- Reports continued progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare disease - - New data from pilot phase of ongoing CheMo4M...
05-27 19:00
Earnings Scheduled For May 27, 2025
Companies Reporting Before The Bell • Bank of Nova Scotia (NYSE:BNS) is project...
05-27 16:32
